Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

TRIO-US (Translational Research In Oncology)

Welcome To TRIO-US

TRIO (Translational Research In Oncology) is a not-for-profit clinical research organization that is dedicated to advancing translational cancer research by bringing forward innovative and targeted therapeutic concepts into the clinical trial setting. The TRIO entity is a merger of CIRG (Cancer International Research Group) and TORI (Translational Oncology Research International), now named TRIO-US, and the wide group of preclinical/clinical researchers at the UCLA Jonsson Comprehensive Cancer Center. Together, TRIO represents an exciting innovative translational research program, enabling “proof of concept” up to registrational phase III trials in different setting such as breast, ovary, GI and other cancers.

The TRIO-US network:

  • Manages clinical trials at more than 50 community-based oncology practices representing 155 physicians at 24 locations across the United States.  A full list of current TRIO-US sites is listed at the bottom of this page.
     
  • Is dedicated to the search for innovative and quality treatment options for its cancer patients. The network provides patients access to clinical trials with promising new treatments that are usually only available to patients in larger cities and at academic centers.
     
  • Offers the same high-quality UCLA standards as in campus-based studies.
     
  • Conducts both industry-sponsored and TRIO-US investigator-initiated trials.
     
  • Conducted trials that have led to the approvals of various targeted therapies such as Herceptin, Avastin, Tarceva, Gleevec and Sutent, for breast, lung, kidney and colorectal cancers, as well as chronic myelogenous leukemia and gastrointestinal stromal tumors.

“We are certain this is the most effective means to deliver the latest and best that American medicine has to offer to patients,” says Dr. Dennis Slamon, Founder and Chair of the TRIO group. “We have very carefully selected the finest cancer physicians and clinics to affiliate with, so we can offer patients the state of-the-art in cancer care”.

TRIO-US Team

Founder and Chairman: Dennis Slamon, M.D., Ph.D.
Director: Isett Laux, Ph.D.
Regulatory Manager: Ekaette Akpan
Chief Financial Officer: Jim Muff

TRIO-US Network Sites

California

Colorado

Florida

Georgia

Illinois

Indiana

Nevada

Maryland

North Carolina

Pennsylvania

 
Last updated: 5/3/2013 10:08:16 AM